Ampio Pharmaceuticals (NYSE:AMPE) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Rating) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

Shares of Ampio Pharmaceuticals stock opened at $0.50 on Wednesday. The stock has a 50-day simple moving average of $0.09. The company has a market cap of $113.12 million, a price-to-earnings ratio of -4.54 and a beta of 1.60. Ampio Pharmaceuticals has a 1 year low of $0.02 and a 1 year high of $1.62.

Ampio Pharmaceuticals Company Profile

(Get Rating)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19.

See Also

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.